HDAC2 and breast cancer: In our previous study, the pharmacological and siRNA-mediated blockade of HDAC2 or HDAC3 resulted in the down-regulation of the intermediate-conductance Ca2+-activated K+ channel KCa3.1 in human breast cancer YMB-1 cells [31].